Managing Type 2 Diabetes: The Impact of Secure Patient-Provider Messaging
Secure messaging presents an opportunity for patients and healthcare providers to collaborate on self-management issues like glycemic control, diet, and exercise.
Type 2 Diabetes
TYPE 2 DIABETES
-
-
In-Hospital Tramadol Use Increases Hypoglycemia Risk in T1D, T2D
Results indicate that blood glucose monitoring should be conducted in hospitalized patients with diabetes. -
Type 2 Diabetes and Antidepressant Drug Use: Is There a Causal Link?
Updated meta-analysis confirms the association between antidepressant drug (AD) use and incident diabetes. Future studies should be aimed at evaluating the effect of single AD on the risk of developing T2D. -
Addressing Psychological Insulin Resistance in Patients With Diabetes
Learn about strategies to reduce a patient’s reluctance to initiate insulin therapy, a phenomenon called psychological insulin resistance.
Video
Latest News
Sotagliflozin Reduces Risk for Adverse CV Events in Diabetic Kidney Disease
Sotagliflozin might help patients with diabetes and chronic kidney disease who are hospitalized with heart failure avoid a readmission, study results suggest.
Group-Based Lifestyle Intervention Reduces T2DM Progression
A low-cost, group-delivered lifestyle intervention is associated with a significantly lower risk for progression to type 2 diabetes among high-risk individuals.
SGLT2 Inhibitors Reduce CV, Kidney Event Risk Regardless of Metformin Use
Investigators evaluated whether the effects of SGLT2 inhibitors on cardiovascular, kidney and mortality outcomes are the same with and without concomitant metformin use.
Lifestyle Intervention and Risk for MI, Heart Failure in T2D
An intensive lifestyle intervention was found to be associated with a significant loss of fat mass and lean mass in adults with type 2 diabetes.
CDC: 26.4% of Adults With Diabetes Meet Goals to Prevent Complications
About one in four U.S. adults (26.4 percent) with diabetes meet the combined goals for preventing or delaying complications of diabetes.
Increased Risk for Type 2 Diabetes Among Adolescents With Fatty Liver
This study evaluated risk for type 2 diabetes among more than 1 million adolescents in Israel with and without nonalcoholic fatty liver disease.
Can NRTIs Be Repurposed to Reduce Risk for T2D Development?
Evidence suggests that a class of drugs used to treat HIV and hepatitis B can reduce a patient’s risk for developing type 2 diabetes.
Efficacy of Endothelin Receptor Antagonists for Renal Protection in Diabetic Kidney Disease
Atrasentan outperformed both avosentan and bosentan for renoprotection in patients with type 2 diabetic kidney disease.
Apabetalone Prevents Post-ACS MACE Risk in Comorbid CKD, Diabetes
In the BETonMACE trial, CKD patients with type 2 diabetes who recently experienced acute coronary syndrome who received apabetalone had a significant 50% reduction in the risk for major cardiovascular events compared with placebo.
Finerenone Slows CKD Progression in Diabetic Kidney Disease
Finerenone vs placebo added to standard therapy was associated with a significant 18% reduction in the risk for major adverse kidney events in patients with both chronic kidney disease and type 2 diabetes mellitus.
-
Loading...
-
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Type 2 Diabetes
